JULY 2021 - FINEXSI ISSUED ITS REPORT AS INDEPENDENT EXPERT IN CONNECTION WITH THE PROPOSED PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT (OPR-RO) INITIATED BY CALLIDITAS THERAPEUTICS AB FOR THE SHARES OF GENKYOTEX S.A.

Month: July 2021

JULY 2021 – FINEXSI ISSUED ITS REPORT AS INDEPENDENT EXPERT IN CONNECTION WITH THE PROPOSED PUBLIC BUY-OUT OFFER FOLLOWED BY A SQUEEZE-OUT (OPR-RO) INITIATED BY CALLIDITAS THERAPEUTICS AB FOR THE SHARES OF GENKYOTEX S.A.

Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% of the shares of GENKYOTEX SA, a biopharmaceutical company specialised in the development of NOX therapies. CALLIDITAS THERAPEUTICS AB therefore announced on July 28, 2021 its intention to launch a public...

Read more...

JULY 2021 – FINEXSI ISSUED ITS REPORT AS INDEPENDENT EXPERT IN CONNECTION WITH THE PROPOSED MIXED PUBLIC OFFER FOR THE SHARES OF SFL

In April 2021, the Board of Directors of Société Foncière Lyonnaise (SFL) (a real estate company dedicated to the prime tertiary segment) was informed of a series of transactions initiated by Colonial, its majority shareholder, in relation to the evolution of the existing partnership between SFL and Predica. These transactions included a...

Read more...

JULY 2021 – OLIVIER PERONNET, FOUNDING PARTNER OF FINEXSI, WILL SPEAK AT THE “RENCONTRES ECONOMIQUES D’AIX-EN-PROVENCE”

On July 3, Olivier PERONNET, Founding Partner of Finexsi, will speak at « Les Rencontres Economiques d'Aix-en-Provence », as a member of the panel discussion on « Financing the real economy ».   Join us live at 3:40pm :   Session 23 - Financer l'économie réelle - Les Rencontres Économiques...

Read more...